MedPath

Preventing asthma exacerbations in children aged 6 to 12 years with atopic asthma using a winter only treatment with OM-85

Phase 3
Conditions
Asthma
Atopy
Respiratory - Asthma
Registration Number
ACTRN12614000062628
Lead Sponsor
The University of Queensland
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Stopped early
Sex
All
Target Recruitment
19
Inclusion Criteria

Children of either sex, aged 6 to younger than 12 years, with current asthma;

At least one moderate or severe exacerbation of asthma, as defined by the ATS/ERS statement on asthma control and exacerbation, in the past 12 months;

A C-ACT score of less than or equal to 19;

Positive skin prick test to either mould, house dust mite or cat;

Participants who, in the opinion of the site investigator, are able to comply with the protocol for its duration;

Written informed consent signed and dated by parent/legal guardian according to local regulations.

Exclusion Criteria

Children who has previously received OM-85 in the past 3 months;

If female and currently pregnant, breastfeeding or of child-bearing potential without reliable contraceptive methods;

Participation in another randomized controlled trial within the 3 months preceding inclusion in this study;

A significant medical disease or condition other than asthma that is likely to interfere with the child’s ability to complete the entire protocol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The mean number of lower respiratory events per patient over the treatment period.<br><br>Lower respiratory events are defined as a wheezy lower respiratory infection lasting two or more days requiring additional asthma medication. Events will be recorded via patient daily diary.[- Two weeks after the last dose of treatment (5 months after start of treatment), and<br>- Three months after last dose of treatment]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath